@article {Ryan2022.09.22.22280180, author = {Feargal J. Ryan and Todd S. Norton and Conor McCafferty and Stephen J. Blake and Natalie E. Stevens and Jane James and Georgina L. Eden and Yee C. Tee and Saoirse C. Benson and Makutiro G. Masavuli and Arthur EL Yeow and Arunasingam Abayasingam and David Agapiou and Hannah Stevens and Jana Zecha and Nicole L. Messina and Nigel Curtis and Vera Ignjatovic and Paul Monagle and Huyen Tran and James D. McFadyen and Rowena A. Bull and Branka Grubor-Bauk and Miriam A. Lynn and Rochelle Botten and Simone E. Barry and David J. Lynn}, title = {A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses}, elocation-id = {2022.09.22.22280180}, year = {2022}, doi = {10.1101/2022.09.22.22280180}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We longitudinally profiled immune responses in 102 adults who received BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (Oxford-AstraZeneca) as their primary vaccinations. Bloods were collected pre-vaccination, 1-7 days after the 1st, 2nd and 3rd doses (BNT162b2 or mRNA-1273) to assess innate and early adaptive responses, and \~{}28 days after the 2nd and 3rd doses to assess immunogenicity. Using a multi-omics approach including RNAseq, cytokine multiplex assay, proteomics, lipidomics, and flow cytometry we identified key differences in the immune responses induced by the ChAdOx1-S and BNT162b2 vaccines that were correlated with subsequent antigen-specific antibody and T cell responses or vaccine reactogenicity. We observed that vaccination with ChAdOx1-S but not BNT162b2 induced a memory-like response after the first dose, which was correlated with the expression of several proteins involved in complement and coagulation. The COVID-19 Vaccine Immune Responses Study (COVIRS) thus represents a major resource to understand the immunogenicity and reactogenicity of these COVID-19 vaccines.Competing Interest StatementV.I., P.M. and C.M. received funding from AstraZeneca to undertake the proteomics component of this study. J.Z. is an employee of, and holds or may hold stock, in AstraZeneca. All other authors declare no competing interestsFunding StatementThis work was funded by BioPlatforms Australia, Flinders Foundation and EMBL Australia Group Leader funding awarded to DJL. The proteomics component of this study was funded by AstraZeneca. This work was also supported in part by a MRFF Coronavirus research response grant (APP2015305) and The Hospital Research Foundation Group COVID-19-SA grant. We thank SA Pathology for help with sample collection and the South Australian Genomics Centre (SAGC) for help with RNA sequencing. The SAGC is supported by the National Collaborative Research Infrastructure Strategy (NCRIS) via BioPlatforms Australia and by the SAGC partner institutes.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of CALHN Human Research Ethics Committee, Adelaide, Australia gave ethical approval for this work (Approval No. 14778).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMulti-omics datasets and R code are available via the Lynn Laboratory BitBucket (https://bitbucket.org/lynnlab/covirs). RNASeq data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE199750. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD036608 https://bitbucket.org/lynnlab/covirs Multi-omics datasets and R code are available via the Lynn Laboratory BitBucket (https://bitbucket.org/lynnlab/covirs). RNASeq data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE199750. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD036608 https://bitbucket.org/lynnlab/covirs}, URL = {https://www.medrxiv.org/content/early/2022/09/23/2022.09.22.22280180}, eprint = {https://www.medrxiv.org/content/early/2022/09/23/2022.09.22.22280180.full.pdf}, journal = {medRxiv} }